{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:18:24Z","timestamp":1787505504540,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pregnancy Childbirth"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Valproate is a teratogenic drug that should be avoided during the preconception period and pregnancy. The aim was to explore general practitioners\u2019 (GPs) prescription patterns over time, describe trends, and explore inter-practice variation within primary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We identified women of childbearing age (12\u201346\u00a0years old) in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) sentinel network. We performed repeated cross-sectional analyses from 2004 to 2018 to determine rates of prescription and a retrospective cohort estimated the prevalence of use of valproate during pregnancy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 2004, 0.31% (95% Confidence Interval (95%CI):0.18 to 0.44%) women were prescribed valproate, decreasing to 0.16% (95%CI:0.07 to 0.24%) by 2018. Among women with epilepsy, the rate fell from 15.2% (95%CI:14.4 to 16.0%) to 8.8% (95% CI:8.2 to 9.7%) over the same period. In 2018, almost two thirds (62.2%) of women who were prescribed valproate had epilepsy only, whereas bipolar disorder and migraine accounted for 15.8% and 7.4% respectively. Contraceptive prescriptions did not increase over time, and only in 2018 was there greater odds of being prescribed contraception (OR 1.41, 95%CI:1.08 to 1.45). Just under a fifth (19.7%) of women were prescribed valproate during their pregnancy; two out of three of these pregnancies were preceded by folic acid prescription (5\u00a0mg). While some practices reduced their rate of valproate prescription, others did not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Regulatory guidelines have changed GPs' prescription patterns in women of childbearing potential for valproate but not for contraception. Further research is needed to identify the barriers of GPs and women of childbearing potential to undertaking contraception.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12884-021-04351-x","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:02:49Z","timestamp":1643263369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Valproate prescription to women of childbearing age in English primary care: repeated cross-sectional analyses and retrospective cohort study"],"prefix":"10.1186","volume":"22","author":[{"given":"Mariangela","family":"Gaudio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanouela","family":"Konstantara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"van Vlymen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"8","key":"4351_CR1","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1212\/WNL.0000000000003637","volume":"88","author":"AG Herzog","year":"2017","unstructured":"Herzog AG, Mandle HB, Cahill KE, Fowler KM, Hauser WA. Predictors of unintended pregnancy in women with epilepsy. Neurology. 2017;88(8):728\u201333.","journal-title":"Neurology"},{"issue":"681","key":"4351_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3399\/bjgp19X701897","volume":"69","author":"LV Watkins","year":"2019","unstructured":"Watkins LV, Cock HR, Angus-Leppan H, Shankar R. Valproate and the Pregnancy Prevention Programme: exceptional circumstances. Br J Gen Pract. 2019;69(681):166\u20137.","journal-title":"Br J Gen Pract"},{"issue":"10","key":"4351_CR3","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","volume":"16","author":"E Perucca","year":"2002","unstructured":"Perucca E. Pharmacological and Therapeutic Properties of Valproate. CNS Drugs. 2002;16(10):695\u2013714.","journal-title":"CNS Drugs"},{"issue":"s426","key":"4351_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/j.1600-0447.2005.00522.x","volume":"111","author":"CL Bowden","year":"2005","unstructured":"Bowden CL, Singh V. Valproate in bipolar disorder: 2000 onwards. Acta Psychiatr Scand. 2005;111(s426):13\u201320.","journal-title":"Acta Psychiatr Scand"},{"key":"4351_CR5","first-page":"CD010611","volume":"6","author":"M Linde","year":"2013","unstructured":"Linde M, Mulleners WM, Chronicle EP, McCrory DC. Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database Syst Rev. 2013;6:CD010611.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4351_CR6","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-018-0898-3","volume":"19","author":"E Vatzaki","year":"2018","unstructured":"Vatzaki E, Straus S, Dogne J-M, Garcia Burgos J, Girard T, Martelletti P. Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. J Headache Pain. 2018;19(1):68.","journal-title":"J Headache Pain"},{"issue":"1","key":"4351_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.reprotox.2009.02.014","volume":"28","author":"A Ornoy","year":"2009","unstructured":"Ornoy A. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol. 2009;28(1):1\u201310.","journal-title":"Reprod Toxicol"},{"issue":"9","key":"4351_CR8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.ejmg.2018.05.008","volume":"61","author":"JK Morris","year":"2018","unstructured":"Morris JK, Garne E, Loane M, Addor M-C, Barisic I, Bianchi F, et al. Prevalence of valproate syndrome in Europe from 2005 to 2014: A registry based multi-centre study. Eur J Med Genet. 2018;61(9):479\u201382.","journal-title":"Eur J Med Genet"},{"key":"4351_CR9","doi-asserted-by":"publisher","first-page":"i5829","DOI":"10.1136\/bmj.i5829","volume":"355","author":"Z Kmietowicz","year":"2016","unstructured":"Kmietowicz Z. Women are unaware of pregnancy risks linked with sodium valproate. BMJ. 2016;355:i5829.","journal-title":"BMJ"},{"issue":"8","key":"4351_CR10","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/bdra.23277","volume":"100","author":"K Fathe","year":"2014","unstructured":"Fathe K, Palacios A, Finnell RH. Brief report novel mechanism for valproate-induced teratogenicity. Birth Defects Res A Clin Mol Teratol. 2014;100(8):592\u20137.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"6","key":"4351_CR11","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1212\/01.WNL.0000154516.43630.C5","volume":"64","author":"DF Wyszynski","year":"2005","unstructured":"Wyszynski DF, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology. 2005;64(6):961\u20135.","journal-title":"Neurology"},{"issue":"4","key":"4351_CR12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.yebeh.2006.08.007","volume":"9","author":"K Viinikainen","year":"2006","unstructured":"Viinikainen K, Eriksson K, M\u00f6nkk\u00f6nen A, Aiki\u00e4 M, Nieminen P, Heinonen S, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006;9(4):636\u201340.","journal-title":"Epilepsy Behav"},{"issue":"1","key":"4351_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2165\/11317640-000000000-00000","volume":"33","author":"R Banach","year":"2010","unstructured":"Banach R, Boskovic R, Einarson T, Koren G. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf. 2010;33(1):73\u20139.","journal-title":"Drug Saf"},{"issue":"5","key":"4351_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/FTD.0000000000000193","volume":"37","author":"YC Kaplan","year":"2015","unstructured":"Kaplan YC, Nulman I, Koren G. Dose-Dependent Risk of Malformations With Antiepileptic Drugs. Ther Drug Monit. 2015;37(5):557\u20138.","journal-title":"Ther Drug Monit"},{"key":"4351_CR15","doi-asserted-by":"publisher","first-page":"107068","DOI":"10.1016\/j.yebeh.2020.107068","volume":"108","author":"EH Reynolds","year":"2020","unstructured":"Reynolds EH, Green R. Valproate and folate: Congenital and developmental risks. Epilepsy and Behavior. 2020;108:107068.","journal-title":"Epilepsy and Behavior"},{"issue":"4","key":"4351_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.14236\/jhi.v23i4.920","volume":"23","author":"Z Tippu","year":"2017","unstructured":"Tippu Z, Correa A, Liyanage H, Burleigh D, McGovern A, Van Vlymen J, et al. Ethnicity Recording in Primary Care Computerised Medical Record Systems: An Ontological Approach. J Innov Heal Informatics. 2017;23(4):799.","journal-title":"J Innov Heal Informatics"},{"issue":"1","key":"4351_CR17","doi-asserted-by":"publisher","first-page":"e100013","DOI":"10.1136\/bmjhci-2019-100013","volume":"26","author":"H Liyanage","year":"2019","unstructured":"Liyanage H, Williams J, Byford R, de Lusignan S. Ontology to identify pregnant women in electronic health records: primary care sentinel network database study. BMJ Heal Care Informatics. 2019;26(1):e100013.","journal-title":"BMJ Heal Care Informatics"},{"issue":"4","key":"4351_CR18","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1136\/qhc.11.4.390-a","volume":"11","author":"D Spiegelhalter","year":"2002","unstructured":"Spiegelhalter D. Funnel plots for institutional comparison. Qual Saf Health Care. 2002;11(4):390\u20131.","journal-title":"Qual Saf Health Care"},{"issue":"6","key":"4351_CR19","first-page":"S55","volume":"180","author":"RW Sanson-Fisher","year":"2004","unstructured":"Sanson-Fisher RW. Diffusion of innovation theory for clinical change. Med J Aust. 2004;180(6):S55.","journal-title":"Med J Aust"},{"issue":"8","key":"4351_CR20","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/s00103-018-2768-1","volume":"61","author":"N Wentzell","year":"2018","unstructured":"Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, et al. Prescribing valproate to girls and women of childbearing age in Germany: Analysis of trends based on claims data. Bundesgesundheitsblatt - Gesundheitsforsch \u2013 Gesundheitsschutz. 2018;61(8):1022\u20139.","journal-title":"Bundesgesundheitsblatt - Gesundheitsforsch \u2013 Gesundheitsschutz"},{"key":"4351_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yebeh.2018.12.002","volume":"92","author":"L Jacob","year":"2019","unstructured":"Jacob L, Schmitz B, Bohlken J, Kostev K. Trends in valproate use in patients in Germany between 2009 and 2017. Epilepsy Behav. 2019;92:26\u201330.","journal-title":"Epilepsy Behav"},{"key":"4351_CR22","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.seizure.2016.01.019","volume":"36","author":"S Murphy","year":"2016","unstructured":"Murphy S, Bennett K, Doherty CP. Prescribing trends for sodium valproate in Ireland. Seizure. 2016;36:44\u20138.","journal-title":"Seizure"},{"issue":"10091","key":"4351_CR23","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0140-6736(17)31866-4","volume":"390","author":"B Casassus","year":"2017","unstructured":"Casassus B. France bans sodium valproate use in case of pregnancy. Lancet. 2017;390(10091):217.","journal-title":"Lancet"},{"key":"4351_CR24","doi-asserted-by":"publisher","first-page":"k1596","DOI":"10.1136\/bmj.k1596","volume":"361","author":"H Angus-Leppan","year":"2018","unstructured":"Angus-Leppan H, Liu RSN. Weighing the risks of valproate in women who could become pregnant. BMJ. 2018;361:k1596.","journal-title":"BMJ"},{"issue":"10","key":"4351_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1056\/NEJMsa1801495","volume":"379","author":"M Minchin","year":"2018","unstructured":"Minchin M, Roland M, Richardson J, Rowark S, Guthrie B. Quality of Care in the United Kingdom after Removal of Financial Incentives. N Engl J Med. 2018;379(10):948\u201357.","journal-title":"N Engl J Med"}],"container-title":["BMC Pregnancy and Childbirth"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-04351-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12884-021-04351-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12884-021-04351-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T06:04:58Z","timestamp":1643263498000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpregnancychildbirth.biomedcentral.com\/articles\/10.1186\/s12884-021-04351-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4351"],"URL":"https:\/\/doi.org\/10.1186\/s12884-021-04351-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-52158\/v1","asserted-by":"object"}]},"ISSN":["1471-2393"],"issn-type":[{"value":"1471-2393","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"1 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was classified as \u201cusual practice\u201d by the Heath Research Authority (HRA) \/Medical Research Council (MRC) \u201cIs this research\u201d decision tool (\n                      \n                      ). A protocol, clearly defining the purpose of the request and use of data, was submitted in order to gain ethical permission by RCGP RSC commission who approved this study on the 25\/04\/2018 (reference: RSC_1718).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nothing to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}